An observational study in Osteosarcoma, sponsored by West China Hospital. Status unknown at 1 site in China. Per ClinicalTrials.gov, last updated 2022-01-31.
Sponsored by West China Hospital · Observational
The aim of this study was to developed and validated models to predict therapeutic responses and patients' survivals in patients with osteosarcoma and compared these models with currently available models.
The investigator performed a retrospective-prospective cohort study with the aim of developing and validating comprehensive models to predict treatment responses and survival outcomes in patients with biopsy-proven osteosarcoma. Secondly, the investigator aimed to compare the predictive accuracy with currently available noninvasive model.
437 studies on the registry are indexed under Osteosarcoma; 116 are open to participants now.
This study's planned enrollment of 800 is above the median of 100 across 88 observational studies indexed under Osteosarcoma.
Browse Osteosarcoma studies →West China Hospital is the lead sponsor of 483 studies on the registry; 240 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with osteosarcoma who were diagnosed histologically with definite pathologic specimens.
Exclusion Criteria:
The internal cohort was retrospectively enrolled in West China Hospital, Sichuan University from June 2010 and December 2020. It is a training and internal validation cohort.
Other: Prediction model
The same inclusion/exclusion criteria were applied for the same center prospectively. It is an external validation cohort.
Other: Prediction model
We develop and validate clinical models to predict treatment responses and survival outcomes in patients with biopsy-proven with osteosarcoma.
Treatment response
The primary outcome was the evaluation of treatment response to individualized therapy in patients with osteosarcoma.
Time frame: At least 1-year follow up
Progression-free survival outcomes
The endpoint was defined as the occurrence of progression or recurrence, or the last follow-up. Patients were followed from the day of histological diagnosis until the occurrence of progression or recurrence, or last visit. The outcome was evaluated by an experienced oncologist in each center every 3-6 months. At each visit, a medical history, physical examination, and standard laboratory tests were performed.
Time frame: At least 5-year follow up
Overall survival outcomes
The endpoint was defined as the occurrence of death or the last follow-up. Patients were followed from the day of histological diagnosis until the occurrence of progression or recurrence or last visit. The outcome was evaluated by an experienced oncologist in each center every 3-6 months. At each visit, a medical history, physical examination, and standard laboratory tests were performed.
Time frame: At least 5-year follow up
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
West China Hospital